{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-23-051347","form_type":"8-K","ticker":"ABVC","cik":"0001173313","company_name":"ABVC BIOPHARMA, INC.","filed_at":"2023-06-23T23:59:59+00:00","discovered_at":"2026-05-14T18:03:38.144177+00:00","generated_at":"2026-06-13T17:38:39.073221+00:00","sec_items":["5.02","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"ABVC BioPharma appoints Dr. Uttam Patil as CEO after Dr. Howard Doong resigns","bullets":["Dr. Howard Doong resigned as CEO effective June 21, 2023; no disagreement with Company operations.","Board appointed Dr. Uttam Yashwant Patil as CEO and President effective June 23, 2023.","Dr. Patil also serves as COO and Scientific Officer of subsidiary BioKey since May 2023.","New employment agreement provides one-year term, salary paid in stock options, and severance in stock shares.","He holds a Ph.D. in Chemistry from National Tsing Hua University and previously served as post-doctoral fellow at NTNU."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-23-051347","json":"https://secwatch.observer/filing/0001213900-23-051347.json","markdown":"https://secwatch.observer/filing/0001213900-23-051347.md","text":"https://secwatch.observer/filing/0001213900-23-051347.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1173313/000121390023051347/0001213900-23-051347-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1173313/000121390023051347/ea180822-8k_abvcbiopharm.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-13T17:38:39.073221+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"430ebb691c","claim":"Dr. Uttam Yashwant Patil was appointed as Chief Executive Officer at ABVC BIOPHARMA, INC..","evidence_excerpt":"The Company’s board of directors appointed Dr. Uttam Yashwant Patil to replace Dr. Doong as the Company’s CEO.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1173313/000121390023051347/0001213900-23-051347-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Executive Officer"}],"fact_type":"executive_change"},{"claim_id":"6fb6cc8ce2","claim":"Dr. Howard Doong resigned as Chief Executive Officer at ABVC BIOPHARMA, INC..","evidence_excerpt":"Dr. Howard Doong, the Chief Executive Officer (“CEO”) of ABVC BioPharma, Inc. (the “Company”), notified the Company of his resignation, effective June 21, 2023.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1173313/000121390023051347/0001213900-23-051347-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Chief Executive Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}